9 min listen
John Collinge on a treatment for CJD
John Collinge on a treatment for CJD
ratings:
Length:
15 minutes
Released:
Mar 16, 2022
Format:
Podcast episode
Description
John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.
Released:
Mar 16, 2022
Format:
Podcast episode
Titles in the series (100)
The Lancet Neurology: December 08, 2008 by The Lancet Neurology in conversation with